- Wondering whether Natera at US$203.69 is offering good value or asking too much from investors? This article walks through the key signals that can help you judge the current pricing for yourself.
- The stock is up 3.4% over the last week, roughly flat over the past month with a decline of 0.8%, down 11.0% year to date, yet still up 33.6% over the last year and delivering a very large 3 year return and 120.0% over 5 years.
- Recent coverage around Natera has focused on its position in the broader pharmaceuticals and biotech space and how investors are weighing growth potential against ongoing risks. This mix of enthusiasm and caution provides useful context when thinking about whether the current share price is justified.
- Natera currently holds a valuation score of 4/6, which reflects how often it screens as undervalued across several methods, and the next sections break down those approaches before circling back to a more complete way of thinking about value at the end of the article.
Approach 1: Natera Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today to estimate what the business might be worth right now.
For Natera, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company’s last twelve month Free Cash Flow is about US$90.9 million. Analyst and extrapolated projections suggest Free Cash Flow reaching US$2.5 billion in 2035, with intermediate estimates such as US$115 million in 2026 and US$731 million in 2029. All of these future cash flows are converted into today’s dollars using a discount rate. This results in an estimated present value per share.
On this basis, the DCF model suggests an estimated intrinsic value of about US$305.18 per share, compared with the current share price of US$203.69. That implies the stock is trading at roughly a 33.3% discount to this DCF estimate, indicating a notable difference between the market price and this cash flow based valuation.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Natera is undervalued by 33.3%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.
Approach 2: Natera Price vs Sales
For companies where earnings are limited or volatile, the P/S ratio is often a more useful yardstick because it compares what you pay for each dollar of revenue rather than profit. Investors typically accept a higher P/S ratio when they expect stronger revenue growth or see lower risk, and look for a lower ratio when growth is uncertain or risks feel higher.
Natera currently trades on a P/S ratio of 11.66x. This sits slightly above the Biotechs industry average of 10.78x and below the peer group average of 12.98x, so on simple comparisons the stock is around the middle of the pack. Simply Wall St’s Fair Ratio for Natera is 7.68x, which is a proprietary estimate of what the P/S ratio might be given factors such as the company’s earnings growth profile, industry, profit margins, market cap and specific risks.
This Fair Ratio can give a more tailored reference point than broad peer or industry comparisons because it attempts to adjust for those company specific characteristics rather than treating all biotechs as similar. Compared with this Fair Ratio of 7.68x, the current P/S of 11.66x screens as higher.
Result: OVERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Natera Narrative
Earlier it was mentioned that there is an even better way to think about value than any single metric, and that is through Narratives. This simply means writing a clear story about Natera, linking your view of its tests, clinical progress, AI investments and regulatory risks to a set of numbers such as future revenue, earnings, margins and a fair value. You can then compare that fair value with today’s price on Simply Wall St’s Community page to see whether your story suggests the stock is expensive or cheap. The platform keeps those Narratives updated as new earnings, guidance, clinical data or legal updates arrive, and shows how different investors can look at the same stock in very different ways. For example, one Narrative might lean closer to the bullish US$300 fair value with stronger revenue growth and a 16.2% margin assumption, while another might sit nearer US$206.81 with lower growth and a 14.8% margin assumption. Your job is to decide which story, and which set of numbers, feels more realistic for you.
Do you think there's more to the story for Natera? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com